Mirae Asset Global Investments Co., Ltd. Arbutus Biopharma Corp Transaction History
Mirae Asset Global Investments Co., Ltd.
- $22.5 Billion
- Q3 2024
A detailed history of Mirae Asset Global Investments Co., Ltd. transactions in Arbutus Biopharma Corp stock. As of the latest transaction made, Mirae Asset Global Investments Co., Ltd. holds 6,828 shares of ABUS stock, worth $21,781. This represents 0.0% of its overall portfolio holdings.
Number of Shares
6,828
Previous 5,634
21.19%
Holding current value
$21,781
Previous $17,000
52.94%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding ABUS
# of Institutions
155Shares Held
99.5MCall Options Held
2.31MPut Options Held
525K-
Morgan Stanley New York, NY21.7MShares$69.2 Million0.01% of portfolio
-
Whitefort Capital Management, LP New York, NY12.9MShares$41 Million26.34% of portfolio
-
Black Rock Inc. New York, NY11.6MShares$36.9 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.92MShares$28.5 Million0.0% of portfolio
-
Two Seas Capital LP Rye, NY8.39MShares$26.8 Million10.86% of portfolio
About Arbutus Biopharma Corp
- Ticker ABUS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 149,951,008
- Market Cap $478M
- Description
- Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...